Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.14)
# 1,231
Out of 4,502 analysts
112
Total ratings
42.52%
Success rate
1.72%
Average return
Main Sectors:
17 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Market Outperform | $24 → $21 | $9.06 | +131.79% | 8 | Jul 18, 2024 | |
| ELEV Elevation Oncology | Reiterates: Market Outperform | $7 | $2.89 | +142.21% | 4 | Jul 15, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $2.27 | +120.26% | 10 | Jun 20, 2024 | |
| CLLS Cellectis | Reiterates: Market Outperform | $6 | $2.05 | +192.68% | 6 | May 31, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $0.95 | +1,161.03% | 9 | May 13, 2024 | |
| MGNX MacroGenics | Maintains: Market Outperform | $22 → $16 | $5.50 | +190.91% | 10 | May 10, 2024 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $57.57 | +49.38% | 11 | May 9, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Market Outperform | $15 | $8.79 | +70.65% | 8 | Apr 30, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Market Outperform | $14 → $17 | $8.37 | +103.11% | 3 | Apr 25, 2024 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $10 → $16 | $9.13 | +75.25% | 7 | Apr 22, 2024 | |
| NTBL Notable Labs | Reiterates: Market Outperform | $9 | $0.58 | +1,449.05% | 3 | Apr 15, 2024 | |
| EXEL Exelixis | Reiterates: Market Outperform | $27 | $22.96 | +17.60% | 11 | Apr 10, 2024 | |
| MNDY monday.com | Maintains: Buy | $240 → $280 | $236.10 | +18.59% | 3 | Mar 5, 2024 | |
| GBIO Generation Bio Co. | Downgrades: Market Perform | n/a | $3.42 | - | 7 | Oct 23, 2023 | |
| TWO Two Harbors Investment | Maintains: Market Outperform | $18 → $18 | $13.47 | +33.63% | 1 | Jan 26, 2023 | |
| NTLA Intellia Therapeutics | Downgrades: Market Perform | n/a | $26.42 | - | 8 | Jan 19, 2023 | |
| LOGC ContextLogic | Maintains: Market Outperform | $2 → $3 | $5.71 | -47.46% | 3 | May 10, 2022 |
Relay Therapeutics
Jul 18, 2024
Maintains: Market Outperform
Price Target: $24 → $21
Current: $9.06
Upside: +131.79%
Elevation Oncology
Jul 15, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $2.89
Upside: +142.21%
Taysha Gene Therapies
Jun 20, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $2.27
Upside: +120.26%
Cellectis
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $2.05
Upside: +192.68%
Vor Biopharma
May 13, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.95
Upside: +1,161.03%
MacroGenics
May 10, 2024
Maintains: Market Outperform
Price Target: $22 → $16
Current: $5.50
Upside: +190.91%
CRISPR Therapeutics AG
May 9, 2024
Reiterates: Market Outperform
Price Target: $86
Current: $57.57
Upside: +49.38%
Terns Pharmaceuticals
Apr 30, 2024
Reiterates: Market Outperform
Price Target: $15
Current: $8.79
Upside: +70.65%
Acrivon Therapeutics
Apr 25, 2024
Maintains: Market Outperform
Price Target: $14 → $17
Current: $8.37
Upside: +103.11%
Benitec Biopharma
Apr 22, 2024
Maintains: Market Outperform
Price Target: $10 → $16
Current: $9.13
Upside: +75.25%
Notable Labs
Apr 15, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $0.58
Upside: +1,449.05%
Exelixis
Apr 10, 2024
Reiterates: Market Outperform
Price Target: $27
Current: $22.96
Upside: +17.60%
monday.com
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $236.10
Upside: +18.59%
Generation Bio Co.
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $3.42
Upside: -
Two Harbors Investment
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $13.47
Upside: +33.63%
Intellia Therapeutics
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $26.42
Upside: -
ContextLogic
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $5.71
Upside: -47.46%